Apologize in advance for length of message but hopefully it is meaningful and not remotely off topic.
Straight from the horse's mouth:
Back when men were men and science was science - or something like that - Dr. Edgar Ribi got FDA approval of a vaccine adjuvant for treating horse cancers without the antigen that directs the immune system to the appropriate target like an earlier human bladder vaccine.
Closing In on the Cancer Vaccine After long frustration, researchers are finally learning how to enlist the immune system to destroy tumors.
(FORTUNE Magazine) By David Stipp December 7, 1998
(FORTUNE Magazine) – More than a century ago doctors noticed a curious coincidence: Cancer patients' tumors sometimes shriveled after the patients contracted bacterial infections. That inspired the idea of cancer vaccines, which would stir the body's immune system to attack tumor cells as if they were germs, replicating what seemed to have happened in the lucky patients. Unlike the familiar preventive shots we get to ward off the measles, flu, and other infectious ills, cancer vaccines would be therapeutic: Doctors would administer them only after disease struck, to focus the immune system's xenophobia on the growths within....
>On Tuesday, the Microsoft founder held an "Ask Me Anything" event on Reddit. When a user asked, "Do you think in the near future, we will have another financial crisis similar to the one in 2008?" Gates replied with a stern — but still optimistic — warning.
"Yes. It is hard to say when but this is a certainty," Gates said. "Fortunately we got through that one reasonably well."
Gates then deferred to his good friend and fellow billionaire philanthropist Warren Buffett, saying, "Warren has talked about this and he understands this area far better than I do."<
Yah, sure, right you are, Bill.
Elephant philanthropists and philosophers like Bill Gates and Warren Buffett, who have made their mark, have no cares, no concerns when they step on ants like a small biotech with a real cancer cure that has vanished into the ether as even another better one is endangered by corrupt and foolish management - ADXS.
Bill and Warren were obviously weighty factors in the informal Seattle billionaire boys biotech investment club that financed the rummage sale of Ribi Immunochem Research to an incompetent loudmouth heading up Corixa that went bankrupt.
GSK celebrates 30th anniversary of Hamilton lab site
GSK picked up the only thing of value left from the crash of Corixa for pennies that recently blazed into the headlines powering the the successful malaria vaccine.
Well Dr. Ribi only used cows and horses to test his superior vaccine adjuvant and his path to fame was cut short when the doctor died in a plane crash. His company fell into the hands of clowns until GSK picked up some pieces.
Steven St. Peter, CEO of PETX, has a long way to go to prove he is made of the stuff of the ill-fated Edgar Ribi but he is showing signs of the latter.
From the transcript of the latest teleconference on the PETX 1stQ earnings report:
"In developing GALLIPRANT, we believe Aratana is the first company to validate the EP4 receptor in any species in any geography. [My emphasis] First we validated as a clinical target for pain control in OA with our FDA and EMA approvals. Second, with the impressive sales result we believe EP4 has now been validated from a commercial perspective notwithstanding the relatively competitive nature of the canine OA pain category.
However we do not believe from the research and development perspective nor from the commercial perspective that the EP4 story has been fully written. Generally in therapeutics development, a first in class therapeutic does not end up as the only in class therapeutic.
During the first quarter of 2018, Aratana expanded its pipeline to include a new generation co EP4 receptor antagonist AT-019. Our next steps with AT-019 include progressing manufacturing to support clinical development and establishing the dose. We look forward to updating you on our progress with AT-019 over time.ALLIPRANT, Aratana entered the canine osteoarthritis pain market. The canine osteoarthritis pain market is not as geographically concentrated as the CCL surgery market. I think one needs a large and more geographically dispersed sales force and the OA pain market is very competitive.
This small footnote to the usual dreariness of financial reports has the makings of fame and fortune IMHO.
The deleterious and pathologic actions of PGE 2 are inhibited in varying degrees by steroids, aspirin and cyclo-oxygenase inhibiting NSAIDs; however, administration of these drugs causes decreased production of PGE 2, thereby decreasing or eliminating the homeostatic functions of the molecule. By inhibiting just the EP4 receptor, the homeostatic function of PGE 2 is better maintained. This manuscript will introduce a new class of pharmaceuticals known as the piprant class.
Have fun with the remainder of the abstract and lengthy scientific article as it grabs you. Just this tells me PETX is successful on the cutting edge with a very new concept in its biotech concentrating on pets. PETX has far more than another NSAID or steroid with enormous possibilities.
The growing income [prospect of income if you insist] is nice too.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
- Dr. Edgar Ribi got FDA approval of a vaccine adjuvant for treating horse cancers without the antigen that directs the immune system to the appropriate target like an earlier human bladder vaccine. 
